Coverage
Filings
| Filing | Date |
|---|---|
| Transaction in Own Shares | 2 Jul 2025 |
| Transaction in Own Shares | 1 Jul 2025 |
| Total Voting Rights | 1 Jul 2025 |
| Transaction in Own Shares | 30 Jun 2025 |
| Transaction in Own Shares | 27 Jun 2025 |
| Transaction in Own Shares | 26 Jun 2025 |
| Transaction in Own Shares | 25 Jun 2025 |
| Transaction in Own Shares | 24 Jun 2025 |
| Director Declaration |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 24 Jun 2025 |
| Director/PDMR Shareholding | 24 Jun 2025 |
| Transaction in Own Shares | 23 Jun 2025 |
| Replacement RNS: Linerixibat file accepted by EMA | 23 Jun 2025 |